Quality Assessment: Flat Financial Performance and Weak Profit Growth
Alembic Pharma’s recent quarterly results for Q4 FY25-26 reveal a flat financial performance, with Profit Before Tax (PBT) excluding other income falling sharply by 33.68% to ₹117.88 crores. Operating profit to interest coverage ratio has declined to a low of 10.10 times, signalling reduced buffer to service interest expenses. The quarterly PBDIT also hit a low at ₹227.92 crores, underscoring operational challenges.
Over the last five years, the company’s operating profit has contracted at an annualised rate of -9.97%, indicating poor long-term growth. This sluggish profitability contrasts with the sector’s generally more robust expansion, raising concerns about Alembic’s competitive positioning and earnings quality.
Valuation: Attractive Metrics Amidst Market Underperformance
Despite the weak earnings trajectory, Alembic Pharma’s valuation remains compelling. The company boasts a Return on Capital Employed (ROCE) of 11.6%, which is respectable within the pharmaceuticals industry. Its Enterprise Value to Capital Employed ratio stands at a low 2.5, suggesting the stock is trading at a discount relative to its peers’ historical valuations.
Moreover, the Price/Earnings to Growth (PEG) ratio is 0.8, signalling undervaluation given the company’s profit growth of 28.2% over the past year. This disconnect between valuation and earnings performance may attract value-oriented investors, although caution is warranted given the broader financial and technical concerns.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Trend: Mixed Returns and Debt Servicing Strength
Examining Alembic Pharma’s stock returns relative to the Sensex reveals a mixed picture. While the stock outperformed the benchmark over the past month with an 8.79% gain versus Sensex’s 4.05%, it lagged significantly over the one-year horizon, delivering a negative return of -18.78% compared to the Sensex’s -8.61%. Year-to-date, the stock’s decline of -4.37% was less severe than the Sensex’s -10.23%, but the longer-term underperformance remains a concern.
On a positive note, the company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.28 times. This financial prudence provides some cushion against volatility and operational headwinds, supporting a degree of stability in uncertain market conditions.
Technical Analysis: Shift to Mildly Bearish Outlook
The downgrade to Sell was primarily driven by a change in Alembic Pharma’s technical grade, which shifted from sideways to mildly bearish. Daily moving averages have turned mildly bearish, reflecting recent price weakness. Weekly and monthly technical indicators present a mixed scenario: while the weekly MACD and Bollinger Bands remain mildly bullish, monthly readings are bearish, signalling potential downward pressure in the medium term.
Other technical metrics such as the KST indicator show bullishness on a weekly basis but bearishness monthly, while Dow Theory assessments are mildly bullish across both timeframes. On-balance volume (OBV) remains bullish, suggesting some accumulation by investors despite price softness. However, the overall technical trend points to caution, with the stock price recently falling 2.39% to ₹811.10 from a previous close of ₹831.00, and trading well below its 52-week high of ₹1,064.70.
Market Capitalisation and Institutional Interest
Alembic Pharmaceuticals is classified as a small-cap stock, which typically entails higher volatility and risk compared to larger peers. Institutional investors hold a significant 20.41% stake, indicating confidence from well-resourced market participants who are better equipped to analyse fundamentals. This institutional backing may provide some support to the stock, although it has not prevented recent price declines.
Holding Alembic Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary and Outlook
The downgrade of Alembic Pharmaceuticals Ltd. to a Sell rating by MarketsMOJO reflects a comprehensive evaluation across four key parameters: quality, valuation, financial trend, and technicals. While the company benefits from attractive valuation metrics and strong debt servicing capability, its flat quarterly results, poor long-term profit growth, and a shift to a mildly bearish technical trend have raised red flags.
Investors should weigh the stock’s discounted valuation and institutional interest against the risks posed by operational stagnation and technical weakness. The stock’s underperformance relative to the broader market over the past year further emphasises the need for caution. Those holding Alembic Pharma shares may consider monitoring upcoming quarterly results closely and evaluating alternative investment opportunities within the Pharmaceuticals & Biotechnology sector.
Key Financial and Technical Metrics at a Glance:
- Q4 FY25-26 PBT (excl. other income): ₹117.88 crores, down 33.68%
- Operating profit annual growth (5 years): -9.97%
- ROCE: 11.6%
- Enterprise Value to Capital Employed: 2.5
- PEG Ratio: 0.8
- Debt to EBITDA: 1.28 times
- Technical trend: Mildly bearish (daily moving averages), mixed weekly/monthly indicators
- Stock price: ₹811.10 (down 2.39% on 9 July 2026)
- 52-week range: ₹635.30 - ₹1,064.70
- Institutional holdings: 20.41%
Given these factors, the revised Sell rating aligns with a cautious stance on Alembic Pharmaceuticals, signalling that investors should prioritise risk management and consider portfolio diversification.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
